These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 20638197

  • 1. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Int J Radiat Oncol Biol Phys; 2011 Jul 15; 80(4):1095-101. PubMed ID: 20638197
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 15; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]

  • 3. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y, Guan Y, Zhao WH, Li Q, Xu BH.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 15; 30(12):917-20. PubMed ID: 19173993
    [Abstract] [Full Text] [Related]

  • 4. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 5. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Jun 15; 30(6):456-61. PubMed ID: 19024523
    [Abstract] [Full Text] [Related]

  • 6. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P, Xu BH, Ma F, Li Q.
    Zhonghua Zhong Liu Za Zhi; 2010 Feb 15; 32(2):128-31. PubMed ID: 20403244
    [Abstract] [Full Text] [Related]

  • 7. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE.
    Ann Surg Oncol; 2013 Mar 15; 20(3):811-8. PubMed ID: 22956068
    [Abstract] [Full Text] [Related]

  • 8. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiksyk B, Shenouda M, Raad RA, Taghian AG.
    Ann Surg Oncol; 2014 Oct 15; 21(11):3490-6. PubMed ID: 24841346
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 10. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.
    Clin Oncol (R Coll Radiol); 2012 Apr 10; 24(3):183-9. PubMed ID: 21958729
    [Abstract] [Full Text] [Related]

  • 11. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
    Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris L, Wright JL.
    Breast Cancer Res Treat; 2011 Aug 10; 128(3):899-906. PubMed ID: 21475999
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy.
    Wu SG, He ZY, Li Q, Li FY, Lin Q, Lin HX, Guan XX.
    Breast; 2012 Oct 10; 21(5):657-61. PubMed ID: 22835918
    [Abstract] [Full Text] [Related]

  • 13. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
    Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1337-42. PubMed ID: 15275718
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
    Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG.
    Int J Radiat Oncol Biol Phys; 2010 Mar 01; 76(3):679-84. PubMed ID: 19464815
    [Abstract] [Full Text] [Related]

  • 15. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Mar 01; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 16. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.
    Gwin K, Wheeler DT, Bossuyt V, Tavassoli FA.
    Int J Surg Pathol; 2010 Feb 01; 18(1):27-35. PubMed ID: 19282292
    [Abstract] [Full Text] [Related]

  • 17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Feb 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 18. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb 01; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 01; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

  • 20. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D, Escrig-Sos J, Torrella-Ramos A, Alcalde-Sanchez M, Salvador-Sanchis JL.
    Breast; 2012 Jun 01; 21(3):401-5. PubMed ID: 22579462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.